Merck Serono, a department of Merck KGaA (Darmstadt, Germany), announced today that Cetuximab has been shown to significantly better overall survival (OS) when added to standard treatment for first-line chemotherapy in patients with metastatic colorectal cancer (mCRC) with non-mutated KRAS. It said in a statement.
Merck Serono, Cetuximab increases survival in metastatic tumors.
Posted by robertzertovcki92 191 days ago (http://mradproperties.com)Who Voted for this Story
Pligg is an open source content management system that lets you easily create your own social network.
Comments